Two monoclonal antibodies have been developed to directly target CD47 in different types of cancer and were clinically tested as monotherapy or in combination with other monoclonal antibodies such as cetuximab and rituximab (Table 2) [168,169,170,171]. Here, CD47 is linked to cancer.